Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Masaryk University | OTHER |
Not provided
Not provided
Not provided
Not provided
Alpha-1-antitrypsin deficiency is the most common congenital disease of the respiratory system, leading to early pulmonary emphysema or bronchiectasis. Pulmonary involvement significantly accelerates active cigarette smoking. Patients with alpha-1-antitrypsin deficiency may also have liver cirrhosis, vasculitis, skin or intestinal disorders.
The AATD Registry is a non-interventional multicenter retrospective prospective longitudinal follow-up of patients with alpha-1-antitrypsin deficiency.
The aim of the AATD National Registry is to collect and analyze clinical data in patients with alpha-1 antitrypsin deficiency.
Alpha-1 antitrypsin deficiency is a genetic disorder that may result in lung disease or liver disease. It is assume that it affects 1 person from a cohort of 2,000-5,000 people of the general population. Among patients with COPD, the incidence of the disorder is significantly higher. The prognosis of these patients is incomparably worse compared to classic COPD, because it affects younger patients and the rate of lung tissue loss is faster. The diagnosis is made in patients with pre-existing COPD by examination of the plasma concentration of AAT. In case of its reduction, genetic examination is added. The progression of the disease is rapid and has been shown to be slowed by lifelong augmentation treatment with human AAT. However, in routine clinical practice, it is very difficult to assess the effectiveness of treatment, the progression of lung disease or the prognosis of the disease.
The AATD registry is a non-interventional multicenter retrospective prospective longitudinal follow-up of patients with alpha-1-antitrypsin deficiency. The national registry collects data from all patients with severe or rare AAT deficiency, regardless of the type of organ impairment and age, and thus provides a view of this genetic variation in the Czech population.
The aim of the AATD Registry is to collect and analyse clinical data of patients with alpha-1 antitrypsin deficiency and increase the professional awareness of this hereditary disease.
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Changes of lung function parameters over time | assessement of the rate of decline of FEV1 (ml, %predicted), measured annually | within one year after completion |
| Changes of exercise tolerance tolerance over time | assessment of changes of peak oxygen consumption (peakVO2, ml/kg/min) measured every two years | within one year after completion |
| Changes of respiratory function over time | assessement of the rate of decline of TLco (mol/min/kPa, %predicted), measured annually | within one year after completion |
| Changes of quality of life over time | assessement of the rate of decline of COPD assessment test (CAT, points), measured annually | within one year after completion |
| Relationship of pulmonary function and lung CT densitometry to better determine phenotypes of COPD due to AAT deficiency | Assessement of any possible relationship of primary outcomes 1-3 using LAA (low attenuation area, %) and distribution of emphysema (craniocaudal distribution of emhysema, points) | within one year after completion |
| Measure | Description | Time Frame |
|---|---|---|
| Behavior of individuals with no or minimal lung involvement | Assessement of prognosis of deficient non-smokers by monitoring primary outcome parameters 1-3 | within one year after completion |
| Progression of other organ disorders, namely liver |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients with alpha-1-antitrypsin deficiency
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Katerina Kusalova, Ing | Contact | +420723949465 | kusalova@biostatistika.cz |
| Name | Affiliation | Role |
|---|---|---|
| Jan MD Chlumsky, PhD | Thomayer University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Thomayer university hospital | Recruiting | Prague | Czech Republic | 14059 | Czechia |
Not provided
| ID | Term |
|---|---|
| D019896 | alpha 1-Antitrypsin Deficiency |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Laboratory detection of changes in liver tests (ALT, AST, ALP, GGT, ukat/l)
| within one year after completion |
| D030342 |
| Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D013352 | Subcutaneous Emphysema |
| D004646 | Emphysema |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |